ALX Oncology Holdings (ALXO) SEC Filings: History & Chart

ALX Oncology Holdings Inc.(ALXO)

Biotechnology · South San Francisco, CA

$1.11-0.10 (-8.68%)

Delayed quote: Oct 6, 2026, 2:30 PM EDT

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

South San Francisco, CA

48 employees

www.alxoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jason Lettmann

View full financials

Form	Filing Date	Accepted	Document
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
SC 13G	Jul 27, 2026	Jul 27, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
8-K	Jun 30, 2026	Jun 30, 2026	View filing
8-K	Jun 26, 2026	Jun 26, 2026	View filing
8-K	Jun 11, 2026	Jun 11, 2026	View filing
SC 13D/A	May 27, 2026	May 27, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
10-Q	May 8, 2026	May 8, 2026	View filing
8-K	May 8, 2026	May 8, 2026	View filing
SC 13G/A	Apr 28, 2026	Apr 28, 2026	View filing
ARS	Apr 20, 2026	Apr 20, 2026	View filing
DEF 14A	Apr 20, 2026	Apr 20, 2026	View filing
4	Apr 17, 2026	Apr 17, 2026	View filing
4	Apr 17, 2026	Apr 17, 2026	View filing
3	Apr 17, 2026	Apr 17, 2026	View filing
8-K	Apr 13, 2026	Apr 13, 2026	View filing
4	Mar 23, 2026	Mar 23, 2026	View filing
4	Mar 23, 2026	Mar 23, 2026	View filing
10-K	Mar 9, 2026	Mar 9, 2026	View filing
4	Mar 5, 2026	Mar 5, 2026	View filing
3	Mar 5, 2026	Mar 5, 2026	View filing
8-K	Feb 27, 2026	Feb 27, 2026	View filing
4	Feb 20, 2026	Feb 20, 2026	View filing
4	Feb 19, 2026	Feb 19, 2026	View filing

SEC Filings

Recent Filings